Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECT OF FK-506 ON THE EXPRESSION OF ENDOTHELIN RECEPTOR MESSENGER-RNA IN THE VASCULATURE
Autore:
TAKEDA Y; MIYAMORI I; WU PS; FURUKAWA K; INABA S; TAKEDA R; MABUCHI H;
Indirizzi:
KANAZAWA UNIV,SCH MED,DEPT INTERNAL MED 2,13-1 TAKARA MACHI KANAZAWA ISHIKAWA 920 JAPAN
Titolo Testata:
Journal of cardiovascular pharmacology
, volume: 26, anno: 1995, supplemento:, 3
pagine: 290 - 292
SICI:
0160-2446(1995)26:<290:EOFOTE>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
CYCLOSPORINE; CELLS; RATS;
Keywords:
FK 506; ENDOTHELIN RECEPTOR; MESSENGER-RNA; HYPERTENSION; RAT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
14
Recensione:
Indirizzi per estratti:
Citazione:
Y. Takeda et al., "EFFECT OF FK-506 ON THE EXPRESSION OF ENDOTHELIN RECEPTOR MESSENGER-RNA IN THE VASCULATURE", Journal of cardiovascular pharmacology, 26, 1995, pp. 290-292

Abstract

Tacrolimus (FK 506) is a new, more powerful immunosuppressant and is more effective in the prevention and treatment of allograft rejection in humans than cyclosporine (CysA). The present study was conducted todetermine whether FK 506 increases ET(A) receptor mRNA in blood vessels in rats. FK 506 5 mg/kg/day for 4 weeks increased blood pressure and expression of ET(A) receptor mRNA in mesenteric arteries of Wistar-Kyoto rats. However, 0.5 mg/kg/day of FK 506 did not increase blood pressure or ET(A) mRNA levels in the vasculature. The dose of 0.1 mu M CysA used in clinical practice induced expression of ET(A) receptor mRNAin cultured rat vascular smooth-muscle cells (VSMCs). A clinical dose(0.01 mu M) of FK 506 did not increase expression of ET(A) receptor mRNA in VSMCs. However, 0.1 mu M FK 506 increased the levels of ET(A) receptor mRNA in VSMCs. These results indicate that the upregulating effect of FK 506 on the ET(A) receptor in the vasculature may contributeto the genesis of FK 506-induced hypertension. The lower incidence ofcomplications seen with FK 506 may be due in part to its use at a lower clinical dose compared to that of CysA.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 15:52:25